ClinicalTrials.gg
RecruitingNCT06146296Updated Nov 24, 2023

THE EFFECT OF VITAMIN C ON POST-ORTHODONTIC TREATMENT RELAPSE

A Phase 2/3 interventional study of Local Vitamin C injection and Oral Vitamin C supplement in Orthodontic Relapse, sponsored by Nourhan M.Aly. Recruiting at 1 site in Egypt. Open to participants aged 19 Years to 25 Years. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Nourhan M.Aly · Phase 2/3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 25 Years
Sex
All
01

Study summary

The aim of this study is to evaluate and compare the effect of locally injected and orally administered (systemic) Vitamin C on post-orthodontic treatment relapse

02

Conditions studied

  • Orthodontic Relapse
03

In context

Lead sponsor

Nourhan M.Aly is the lead sponsor of 49 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who were indicated for non-extraction orthodontic treatment.
  • Adult patients with finished orthodontic treatment, using fixed appliance therapy.
  • Patients with good oral hygiene, and a healthy periodontal condition.

Exclusion criteria

Exclusion Criteria:

  • Patients who received sectional fixed appliance therapy.
  • Patients with hypodontia requiring tooth replacement in the retainer, as a temporary measure.
  • Patients requiring fixed bonded retainers.
  • Pregnant and lactating women.
  • Patients with hereditary hemochromatosis.
  • Cancer patients, receiving chemotherapy.
  • Patients with chronic diseases such as diabetes, or those receiving drugs such as , both of which that may affect tooth movement.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Intra-epidermal Vitamin C injection

    Biological: Local Vitamin C injection

  • Active comparator
    Oral Vit-C supplement

    Biological: Oral Vitamin C supplement

  • No intervention
    Control group

Interventions

  • BiologicalLocal Vitamin C injection

    An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.

  • BiologicalOral Vitamin C supplement

    Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.

06

What researchers measure

Primary outcomes

  1. Measurement of post-orthodontic relapse

    Alginate impressions will be taken, and dental models will then be scanned using Sirona inEos X5 CAD/CAM lab scanner, producing 3D digital images of the dental models in the form of stereolithographic (STL) files, which will be subsequently imported into a computer software. Little's Irregularity Index (LII) will be employed for the measurement and the quantitative evaluation of the lower anterior segment alignment. The horizontal linear displacement of the anatomic contact points of each mandibular incisor from the adjacent anatomic point is measured, and the 5 displacements are then summed together. The summed value represents the degree of anterior irregularity as follows: 0 = Perfect alignment. 1-3 = Minimal irregularity. 4-6 = Moderate irregularity. 7-9 = Severe irregularity. 10 = Very severe irregularity.

    Time frame: up to 8 months

  2. Analysis of salivary alkaline phosphatase levels

    Salivary samples will be collected and measured using chemical analysis. Rise in salivary alkaline phosphatase levels reflects inflammation and destruction of healthy tissues suggesting it as a clinical biomarker. The normal level of alkaline phosphatase is 20-140IU/L (international unit per liter) in adults.

    Time frame: up to 8 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Jun 2024, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Nov 24, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Jun 1, 2024
CompletionEst.
Jun 1, 2024
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06146296
Lead sponsor
Nourhan M.Aly
Responsible party
Nourhan M.Aly (Assistant Lecturer of Dental Public Health, University of Alexandria) — Sponsor-investigator
First posted
Nov 24, 2023
Start date
Nov 1, 2023
Primary completion
Jun 1, 2024 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Nov 24, 2023

Study contacts

Samar M Adel, PhD
Contact
orthosamar@gmail.com
1099911526 ext. +20
Samar M Adel, PhD
principal investigator · Alexandria University
Farah Y Eid, PhD
principal investigator · Alexandria University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion